<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01163227</url>
  </required_header>
  <id_info>
    <org_study_id>CAQW051A2205</org_study_id>
    <nct_id>NCT01163227</nct_id>
  </id_info>
  <brief_title>Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Cross-over, Single-dose Study to Evaluate the Effects of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia Including a One Week Multiple-dose Extension to Assess the Persistence of Observed Effects and a Multiple-dose Cross Over Study in Non Smokers Only.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This PoC study is designed to assess the cognitive effects of doses of AQW051 in patients
      with chronic stable schizophrenia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of single oral doses of AQW051 versus placebo on cognitive function as measured by selected CogState tests</measure>
    <time_frame>132 days Part A, 121 days Part B (screening to study completion)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of single oral doses of AQW051 versus placebo on cognitive function as measured by selected MATRICS Consensus Cognitive Battery (MCCB) tests</measure>
    <time_frame>132 days Part A, 121 days Part B (screening to study completion)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of multiple oral doses of AQW051 versus placebo on cognitive function as measured by selected CogState tests and selected MCCB tests</measure>
    <time_frame>132 days Part A, 121 days Part B (screening to study completion)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of the cognitive domains measured by MCCB versus CogState</measure>
    <time_frame>132 days Part A, 121 days Part B (screening to study completion)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics, safety and tolerability of single and multiple doses of AQW051 as compared to placebo</measure>
    <time_frame>132 days Part A, 121 days Part B (screening to study completion)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Schizophrenia Disorders</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AQW051 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AQW051 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AQW051 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (single and multiple doses)</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AQW051 2 mg (single and multiple doses)</intervention_name>
    <arm_group_label>AQW051 Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AQW051 15mg (single and multiple doses)</intervention_name>
    <arm_group_label>AQW051 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AQW051 100mg (single dose), and 50mg (multiple doses)</intervention_name>
    <arm_group_label>AQW051 Dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of schizophrenia

          2. Symptomatically stable and currently treated with a stable regimen for at least 3
             (three) months prior to dosing with one of the following second generation of
             antipsychotics: risperidone, paliperidone, quetiapine, ziprasidone, aripiprazole.

          3. Specific cognitive impairment

          4. Smokers and non-smokers

        Exclusion Criteria:

          1. Current treatment with an anticholinergic or other agent known to adversely interfere
             with the cholinergic system, and/ or treatment with cholinesterase inhibitor within
             the last three (3) months prior to dosing.

          2. Current treatment with conventional antipsychotics (e.g fluphenazine, haloperidol) or
             clozapine.

          3. History of neuroleptic malignant syndrome.

          4. Diagnosis of substance abuse (other than nicotine) within the last month and alcohol
             or substance dependence (other than nicotine) within the last 6 months.

          5. Any clinically significant suicidal ideation (Type 4 or 5 on the Columbia-Suicide
             Severity Rating Scale (C-SSRS) in the last month) or previous history of suicide
             behavior Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PAREXEL (California Clinical Trials Medical Group), 1560 Chevy Chase Drive, Suite 140,</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI Worldwide, 1113 Hospital Dr. Suite 202,</name>
      <address>
        <city>Willingboro</city>
        <state>New Jersey</state>
        <zip>08046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2010</study_first_submitted>
  <study_first_submitted_qc>July 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2010</study_first_posted>
  <disposition_first_submitted>February 18, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>February 18, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 22, 2013</disposition_first_posted>
  <last_update_submitted>March 6, 2013</last_update_submitted>
  <last_update_submitted_qc>March 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hallucinations,</keyword>
  <keyword>psychotic,</keyword>
  <keyword>delusions,</keyword>
  <keyword>cognitive deficits</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

